Trials Sponsors Conditions Drugs Pricing

Conditions

Leg Veins

Outcome Measures

Primary Outcomes (1)

Physician Global Aesthetic Improvement Scale PGAIS
Please rate right leg veins: Circle One * 2 Much Improved * 1 Improved 0 No Change * 1 Worse * 2 Much Worse Please rate left leg veins: Circle One * 2 Much Improved * 1 Improved 0 No Change * 1 Worse * 2 Much Worse
Day 90

Secondary Outcomes (2)

Patient Satisfaction Likert Score for vein improvement
Day 90
Visual Analog Pain Scale Post Treatment
Day 1 and Day 30

Study Arms (2)

Group A Right Leg Treated with glycerin compounded 1% lidocaine and epinephrine

ACTIVE COMPARATOR

Subjects will be treated with foamed sodium tetradecyl sulfate (STS) to both legs. Four weeks later subjects left leg will be treated with glycerin compounded with 1% lidocaine, and right leg will be treated with glycerin compounded with 1% lidocaine and epinephrine.

Drug: Right leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine

Group B Left Leg Treated with glycerin compounded 1% lidocaine and epinephrine

SHAM COMPARATOR

Subjects will be treated with foamed sodium tetradecyl sulfate (STS) to both legs. Four weeks later subjects right leg will be treated with glycerin compounded with 1% lidocaine, and left leg will be treated with glycerin compounded with 1% lidocaine and epinephrine.

Drug: Left leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine

Interventions

Right leg treated with Glycerin compounded with 1% Lidocaine and EpinephrineDrug

Right leg treated with glycerin compounded with 1% lidocaine and epinephrine

Group A Right Leg Treated with glycerin compounded 1% lidocaine and epinephrine

Left leg treated with Glycerin compounded with 1% Lidocaine and EpinephrineDrug

Left leg treated with glycerin compounded with 1% lidocaine and epinephrine

Group B Left Leg Treated with glycerin compounded 1% lidocaine and epinephrine

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
Right leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record
Grouped treatment entry
Left leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age20 Years - 75 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Subjects aged 20-75years.
Fitzpatrick skin types I-VI.

Sponsors & Collaborators

Goldman, Butterwick, Fitzpatrick and Groff
Otherlead

Study Sites (1)

West Dermatology Research Center

San Diego, California, 92121, United States

MeSH Terms

Interventions

LidocaineEpinephrine

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesEthanolaminesAmino AlcoholsAlcoholsBiogenic MonoaminesBiogenic AminesCatecholaminesCatechols

Central Study Contacts

Andrea Pacheco

CONTACT

858-657-1004 apacheco@clderm.com

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: SINGLE
Who Masked: INVESTIGATOR
Purpose: BASIC SCIENCE
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

January 13, 2026

First Posted

January 15, 2026

Study Start

February 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

May 30, 2026

Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Group A Right Leg Treated with glycerin compounded 1% lidocaine and epinephrine

Group B Left Leg Treated with glycerin compounded 1% lidocaine and epinephrine

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Group A Right Leg Treated with glycerin compounded 1% lidocaine and epinephrine

Group B Left Leg Treated with glycerin compounded 1% lidocaine and epinephrine

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations